Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Atypical antipsychotics are widely used in bipolar mania. However, the efficacy of atypical antipsychotics in bipolar depression has not been comprehensively explored. Aims: To evaluate olanzapine monotherapy in patients with bipolar depression. Method: Patients with bipolar depression received olanzapine (5–20mg/day, n = 343) or placebo (n = l71) for 6 weeks. The primary outcome was change from baseline to end-point in Montgomery-Åsberg Depression Rating Scale (MADRS) total score. Secondary outcomes included: Clinical Global impression - Bipolar Version (CGI-BP) scale, 17-item Hamilton Rating Scale for Depression (HRSD-17) and Young Mania Rating Scale (YMRS) scores, and the rate of response (≥50% reduction in MADRS at end-point), recovery (MADRS ≤12 for ≥4 weeks plus treatment completion) and remission (MADRS ≤8). The trial was registered with ClinicalTrials.gov (NCT00510146). Results: Olanzapine demonstrated: significantly greater (P<0.04) improvements on MADRS (least-squares mean change -13.82 v. -11.67), HRSD-17 and YMRS total scores and all CGI-BP subscale scores v. placebo; significantly (P≤0.05) more response and remission, but not recovery; significantly (P<0.01) greater mean increases in weight, fasting cholesterol and triglycerides; and significantly more (P<0.001) patients gained ≥7% body weight. Conclusions: Olanzapine monotherapy appears to be efficacious in bipolar depression. Additional long-term studies are warranted to confirm these results. Safety findings were consistent with the known safety profile of olanzapine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Self-citationCalabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883
Thase, M. E., Macfadden, W., Weisler, R. H., Chang, W., Paulsson, B., Khan, A., & Calabrese, J. R. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000248603.76231.b7 · Cited by 559
Thase, M. E., Jonas, A., Khan, A., Bowden, C. L., Wu, X., McQuade, R. D., Carson, W. H., Marcus, R. N., & Owen, R. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181618eb4 · Cited by 251
Sachs, G. S., Ice, K. S., Chappell, P. B., Schwartz, J. H., Gurtovaya, O., Vanderburg, D. G., & Kasuba, B. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05934 · Cited by 101
Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression
Brown, E., Dunner, D. L., McElroy, S. L., Keck, P. E., Adams, D. H., Degenhardt, E., Tohen, M., & Houston, J. P. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009735 · Cited by 73
Self-citation
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Self-citationMalhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“Randomised controlled trials report that olanzapine (Tohen et al., 2003c, 2012), quetiapine (Calabrese et al., 2005b; McElroy et al., 2010; Thase, 2006; Young et al., 2010) and lurasidone (Loebel et al., 2014a, 2014b) are effective treatments for bipolar depression, but these studies have…”
BackgroundLoebel, A., Cucchiaro, J., Silva, R., Kroger, H., Hsu, J., Sarma, K., & Sachs, G. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070984 · Cited by 341
Loebel, A., Cucchiaro, J., Silva, R., Kroger, H., Sarma, K., Xu, J., & Calabrese, J. R. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070985 · Cited by 293
Guo, M., Mi, J., Jiang, Q., Xu, J., Tang, Y., Tian, G., & Wang, B. (2014) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12265 · Cited by 225
“The MADRS and HRSD-17 were used to assess depressive symptoms.(46,47) In addition, subjects were administered the WMS-R to evaluate cognitive function before drug administration (i.”
MethodDurgam, S., Earley, W., Lipschitz, A., Guo, H., Laszlovszky, I., Németh, G., Vieta, E., Calabrese, J. R., & Yatham, L. N. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15020164 · Cited by 209
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Azorin, J.-M., Yatham, L., Mosolov, S., Möller, H.-J., Kasper, S., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1384850 · Cited by 187
“This study, together with a second study in Japanese patients with bipolar depression (Tohen et al. 2012) was also subject to a pooled analysis (Tohen, Kanba, et al. 2014).”
ResultBahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.030 · Cited by 139
Detke, H. C., DelBello, M. P., Landry, J., & Usher, R. W. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.12.012 · Cited by 135
Selle, V., Schalkwijk, S., Vázquez, G., & Baldessarini, R. (2014) · Pharmacopsychiatry · doi:10.1055/s-0033-1363258 · Cited by 128
Taylor, D. M., Cornelius, V., Smith, L., & Young, A. H. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12343 · Cited by 122
Kadakia, A., Dembek, C., Heller, V., Singh, R., Uyei, J., Hagi, K., Nosaka, T., & Loebel, A. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03220-3 · Cited by 79
“Mean age of onset was only reported in three trials [32, 38, 44], and ranged from 25.”
BackgroundPharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76
Suppes, T., Kroger, H., Pikalov, A., & Loebel, A. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.03.012 · Cited by 65
Kato, T., Ishigooka, J., Miyajima, M., Watabe, K., Fujimori, T., Masuda, T., Higuchi, T., & Vieta, E. (2020) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13137 · Cited by 49
Current landscape, unmet needs, and future directions for treatment of bipolar depression
Frye, M. A., Prieto, M. L., Bobo, W. V., Kung, S., Veldic, M., Alarcon, R. D., Moore, K. M., Choi, D.-S., Biernacka, J. M., & Tye, S. J. (2014) · Journal of Affective Disorders · doi:10.1016/s0165-0327(14)70005-9 · Cited by 36
Is there a ‘weight neutral’ second-generation antipsychotic for bipolar disorder?
Fang, F., Wang, Z., Wu, R., Calabrese, J. R., & Gao, K. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1276284 · Cited by 18
Cai, L., Chen, G., Yang, H., & Bai, Y. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000449 · Cited by 11
Loebel, A., Siu, C., Rajagopalan, K., Pikalov, A., Cucchiaro, J., & Ketter, T. A. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.07.033 · Cited by 11
Metadata
- Authors
- Tohen, M., McDonnell, D. P., Case, M., Kanba, S., Ha, K., Fang, Y. R., Katagiri, H., & Gomez, J.-C.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2012-11
- Volume
- 201
- Issue
- 5
- Pages
- 376-382
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2007929837
- Cited by
- 128
- References
- 8
- FWCI
- 12.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.